Slingshot members are tracking this event:

Phase 2 study of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the treatment of Chronic HBV to complete June 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details "the GS-4774 Phase 2 clinical trial in patients with chronic HBV infection who are currently not receiving treatment, is fully enrolled and the 48-week results are projected to be available in the second half of 2016"
Additional Relevant Details The Phase 2 study of GS-4774 on the treatment of chronic hepatitis B in combination with tenofovir disoproxil fumarate (TDF) is expected to complete in March 2016.  Expect primary data to be released within 30 days after the completion of the study.  The study, by GlobalImmune (commercial rights Gilead Sciences), aims to measure mean change in serum hepatitis B surface antigen (HBsAg) from baseline to Week 24.
Additional Relevant Details Update on 11,4,2016: Initially expected to complete in March 2016, it the completion date is expected in June 2018.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 15, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gs-4774, Chronic Hepatitis B, Phase 2 Study